ABO platform
Engineered glycosidases that cleave A and B antigens from red‑cell surfaces.
Pipeline
From a single drop to a universal supply.
Two platforms, one mission. Our enzymatic ABO conversion and patented Rh‑masking Fab advance independently.
Rh platform (patented)
Designed Fab that masks Rh(D) from immune recognition without cell depletion.
Automation (pending)
Modular bioreactors that produce clinical‑grade universal blood at point of need.
Program
Indication
Platform
Stage
Glycosidases
ABO‑converted universal red blood cells
Engineered glycosidase cocktail
ABO platform
Discovery
Preclinical
Phase I
Phase II
Phase III
ICHOR‑1
Rh(D) Masking
Designed Fab that masks Rh(D)
Rh platform
Discovery
Preclinical
Phase I
Phase II
Phase III
Next milestones
Q4 2026
ICHOR‑1 Phase II interim readout
Safety and transfusion compatibility in 120 patients.
H1 2027
Automation platform
Combined ABO + Rh in an automatic bioreactor
2028
Hospital partnerships
Implement our technology for patients use.